Business Description
Y-mAbs Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US9842411095
Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.42 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10.73 | |||||
| Beneish M-Score | -1.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 55.5 | |||||
| 3-Year EBITDA Growth Rate | 42.3 | |||||
| 3-Year EPS without NRI Growth Rate | 45.2 | |||||
| 3-Year FCF Growth Rate | 35.1 | |||||
| 3-Year Book Growth Rate | -3.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.72 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.56 | |||||
| 9-Day RSI | 52.37 | |||||
| 14-Day RSI | 50.54 | |||||
| 6-1 Month Momentum % | 156.96 | |||||
| 12-1 Month Momentum % | 115.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.52 | |||||
| Quick Ratio | 5.27 | |||||
| Cash Ratio | 3.91 | |||||
| Days Inventory | 211.1 | |||||
| Days Sales Outstanding | 78.9 | |||||
| Days Payable | 280.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 0.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.54 | |||||
| Operating Margin % | -30.27 | |||||
| Net Margin % | -25.26 | |||||
| FCF Margin % | -32.11 | |||||
| ROE % | -20.49 | |||||
| ROA % | -16.04 | |||||
| ROIC % | -109.96 | |||||
| ROC (Joel Greenblatt) % | -315.33 | |||||
| ROCE % | -23.44 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.64 | |||||
| PB Ratio | 6.49 | |||||
| Price-to-Tangible-Book | 6.65 | |||||
| EV-to-EBIT | -22.76 | |||||
| EV-to-EBITDA | -23.43 | |||||
| EV-to-Revenue | 6.89 | |||||
| EV-to-Forward-Revenue | 5.97 | |||||
| EV-to-FCF | -21.45 | |||||
| Price-to-Net-Current-Asset-Value | 7.76 | |||||
| Price-to-Net-Cash | 12.58 | |||||
| Earnings Yield (Greenblatt) % | -4.39 | |||||
| FCF Yield % | -4.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:YMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Y-mAbs Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 84.819 | ||
| EPS (TTM) ($) | -0.49 | ||
| Beta | 0.34 | ||
| Volatility % | 100.41 | ||
| 14-Day RSI | 50.54 | ||
| 14-Day ATR ($) | 0.987043 | ||
| 20-Day SMA ($) | 15.185 | ||
| 12-1 Month Momentum % | 115.34 | ||
| 52-Week Range ($) | 4.6 - 20.9 | ||
| Shares Outstanding (Mil) | 43.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Y-mAbs Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Y-mAbs Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Y-mAbs Therapeutics Inc Frequently Asked Questions
What is Y-mAbs Therapeutics Inc(YMAB)'s stock price today?
The current price of YMAB is $14.97. The 52 week high of YMAB is $20.90 and 52 week low is $4.60.
When is next earnings date of Y-mAbs Therapeutics Inc(YMAB)?
The next earnings date of Y-mAbs Therapeutics Inc(YMAB) is 2024-05-08 Est..
Does Y-mAbs Therapeutics Inc(YMAB) pay dividends? If so, how much?
Y-mAbs Therapeutics Inc(YMAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers